Mirna Therapeutics (NASDAQ: SYBX) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Insider and Institutional Ownership

87.7% of Biogen shares are held by institutional investors. 18.6% of Mirna Therapeutics shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Mirna Therapeutics and Biogen, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirna Therapeutics 0 2 1 0 2.33
Biogen 0 12 11 1 2.54

Mirna Therapeutics currently has a consensus price target of $19.50, suggesting a potential upside of 2.55%. Biogen has a consensus price target of $329.27, suggesting a potential upside of 5.16%. Given Biogen’s stronger consensus rating and higher possible upside, analysts clearly believe Biogen is more favorable than Mirna Therapeutics.

Profitability

This table compares Mirna Therapeutics and Biogen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mirna Therapeutics N/A -44.70% -42.29%
Biogen 28.10% 37.42% 20.12%

Volatility and Risk

Mirna Therapeutics has a beta of 3.59, indicating that its stock price is 259% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Valuation and Earnings

This table compares Mirna Therapeutics and Biogen’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Mirna Therapeutics N/A N/A N/A ($9.59) -1.98
Biogen $11.72 billion 5.65 $6.42 billion $15.23 20.56

Biogen has higher revenue and earnings than Mirna Therapeutics. Mirna Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Mirna Therapeutics on 10 of the 12 factors compared between the two stocks.

About Mirna Therapeutics

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

About Biogen

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company’s product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.